However, previous studies on the selective silencing of S6K2, but not S6K1, in the breast cancer cell line T47D have shown reduced levels of Mcl-1 and BcL-XL, enhancing apoptosis induced by TRAIL and doxorubicin [29]. Here, RPS6KB2 is linked to breast carcinoma.